Bradford

The trials here

What the 7 trials at this site are about, from their registry records.

Conditions

• Asthma6 trials
• COPD1 trial

Phase

• Phase 36 trials
• Phase 21 trial

Status

• Completed3 trials
• Recruiting3 trials
• Active, not recruiting1 trial

Lead sponsor

• GlaxoSmithKline7 trials

Running trials

• Recruiting

  A Study of Efficacy and Safety of Depemokimab Compared With Placebo in Adults and Adolescents With at Risk Type 2 Asthma

  NCT07456033· Phase 3· GlaxoSmithKline· Source

  Contact: Dinesh Saralaya (principal investigator)

• Recruiting

  eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 Inflammation

  NCT07177339· Phase 3· GlaxoSmithKline· Source

  Contact: Dinesh Saralaya (principal investigator)

• Active, not recruiting

  A Dose Finding Study With an Anti-TSLP Antibody (GSK5784283) in Adults Aged 18 to 75 Years of Age With Uncontrolled Asthma

  NCT06748053· Phase 2· GlaxoSmithKline· Source

• Recruiting

  Depemokimab Asthma Imaging and Bronchoscopy Sub-Study

  NCT06979323· Phase 3· GlaxoSmithKline· Source

  Contact: Dinesh Saralaya (principal investigator)

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Asthma2 recruiting
• COPD1 recruiting

Closed trials

• Completed

  An Open-Label Extension Study of GSK3511294 (Depemokimab) in Participants Who Were Previously Enrolled in 206713 (NCT04719832) or 213744 (NCT04718103)

  NCT05243680· Phase 3· GlaxoSmithKline· Source

• Completed

  Placebo-controlled Efficacy and Safety Study of GSK3511294 (Depemokimab) in Participants With Severe Asthma With an Eosinophilic Phenotype

  NCT04719832· Phase 3· GlaxoSmithKline· Source

• Completed

  A Study of GSK3511294 (Depemokimab) Compared With Mepolizumab or Benralizumab in Participants With Severe Asthma With an Eosinophilic Phenotype

  NCT04718389· Phase 3· GlaxoSmithKline· Source